 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
56 News |  |
- | Lypdiso (omega-3 pentaenoic acid) / Matinas
Journal, Head-to-Head: A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. (Pubmed Central) - Apr 9, 2022
P2
EPA+DPA-FFA also reduced triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04177680.
- ||| Lypdiso (omega-3 pentaenoic acid) / Matinas
Trial completion: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Mar 4, 2022
P2, N=100, Completed, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04177680. Active, not recruiting --> Completed
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
Enrollment change, Trial withdrawal: AMPLIFY: Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ?500 mg/dL and <2000 mg/dL (clinicaltrials.gov) - Sep 16, 2021
P3, N=0, Withdrawn, Sponsor: Matinas Biopharma, Inc
Active, not recruiting --> Completed N=300 --> 0 | Not yet recruiting --> Withdrawn
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
Trial completion date, Trial primary completion date: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Feb 23, 2021
P2, N=100, Active, not recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
N=300 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Dec 2020 --> May 2021
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
All boils down to: what is most likely mechanism for benefit seen for Vascepa in its single CVOT? If you are convinced of hypothesis that it's the plasma EPA, then maybe should invest in a CVOT for Lypdiso Your thoughts? @ethanjweiss @pnatarajanmd @lipiddoc @DLBHATTMD (Twitter) - Feb 6, 2021
- || omega-3 pentaenoic acid (MAT9001) / Matinas
$MTNB Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001 https://t.co/yf13YBzqNO (Twitter) - Jan 4, 2021
- |||||||||| Lypdiso (omega-3 pentaenoic acid) / Matinas
New P3 trial: AMPLIFY: Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ?500 mg/dL and <2000 mg/dL (clinicaltrials.gov) - Dec 10, 2020
P3, N=300, Not yet recruiting, Sponsor: Matinas Biopharma, Inc
- || Lypdiso (omega-3 pentaenoic acid) / Matinas, NN1213 / Novo Nordisk
Trial completion: A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (clinicaltrials.gov) - Oct 12, 2020
P1/2, N=48, Completed, Sponsor: Matinas Biopharma, Inc
Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Dec 2020 --> May 2021 Recruiting --> Completed
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
Enrollment closed: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Oct 8, 2020
P2, N=100, Active, not recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Lypdiso (omega-3 pentaenoic acid) / Matinas
Enrollment open, Trial completion date: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Jun 8, 2020
P2, N=100, Recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Feb 2021
- || MAT9001 / Matinas
https://t.co/dyw2EpQ8Ts Assume you read through these too? As @DLBHATTMD noted, strength of EPA dosing matters, one needs to look ahead as well, to MAT9001, results will come by 2021. Meanwhile, we have a lot of data on ethyl esters. CVD reducing. It’s new science. Working. (Twitter) - Jan 24, 2020
- |||| Lypdiso (omega-3 pentaenoic acid) / Matinas
New P2 trial: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Nov 25, 2019
P2, N=100, Not yet recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
- | Lypdiso (omega-3 pentaenoic acid) / Matinas
New P1/2 trial: A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (clinicaltrials.gov) - Dec 6, 2014
P1/2, N=54, Recruiting, Sponsor: Matinas Biopharma, Inc